|
||
| |||||||
|
Diabetic Nephropathy Prevalence, Progression, Prevention and Potential The diabetic microvascular complication, nephropathy, is a condition with high unmet therapeutic needs. It is linked with significant increases in morbidity and mortality risk, and is the most common cause of ESRD in the US and Europe. Despite the efforts to address the increasing incidence of both type 1 and type 2 diabetes, the diabetic population is set to increase by 72% between 2003 and 2025. Report Highlights Newly available data from Datamonitor's Type 2 Diabetes Multi-client study suggests that the prevalence of nephropathy (encompassing microalbuminuria, proteinuria and ESRD) is 48% across the seven countries representing 18.6m type 2 patients. The main focus of therapy in diabetic nephropathy is on tight control of blood pressure. Guidelines have progressively revised the target BP goal downwards, currently at 125/75 mmHg in patients with >1g proteinuria, and now recommend either ACE or ARB therapy as a first line renoprotective anti-hypertensive therapy. Existing anti-hypertensive therapies can only delay the progression of diabetic nephropathy. Research underway to elucidate the etiology and pathways of diabetic microvascular disease has revealed new targets for drug design. Within the next 10 years the most promising compounds will come from the ARI, PKC-beta and AGE inhibitor classes. Reasons to Purchase Access new data from Datamonitor's 380 physician sample survey on the prevalence and progression of diabetic nephropathy in seven major markets. Understand the views of diabetologist and nephrology opinion leaders on the potential for prescribing ACE inhibitors combined with ARBs in diabetes. Identify and assess novel R&D compounds in the diabetic nephropathy pipeline. Scope To evaluate the prevalence and progression of nephropathy in type 2 diabetics To examine the evolution of therapy with an emphasis on the use of renoprotective antihypertensive agents To review ongoing developments in this indication for the angiotensin receptor blockers (ARBs) class To identify and assess the potential for novel approaches for treating the underlying cause of microvascular renal disease Publisher: Datamonitor Cardiovascular Reports To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Cardiovascular.html#a72 |
|
|
